MedTrace Logo

Hemophilia A Research Program

NCT07414511 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2026-02-17

No results posted yet for this study

Summary

This study longitudinally observes the intergenerational (mother-child) continuum in hemophilia A from pregnancy through early childhood. Because the study follows mother-child pairs, the study includes both a maternal cohort and a pediatric cohort. Each cohort has a primary goal: for the mother with a severe hemophilia genotype, the overarching primary goal is to understand the risks for pregnancy-associated bleeding and postpartum hemorrhage (PPH); for the child, the overarching primary goal is to understand the risks, timing, and circumstances of development of anti-FVIII antibodies. From a longitudinal perspective, risks for both bleeding in the mother and anti-FVIII antibody development in the child are expected to be influenced over time by genetic and environmental factors that begin early in (or before) pregnancy. Enrollment of blood relatives is offered to improve power to better understand inherited contributions to bleeding and inhibitor development in the mother-baby pairs.

Conditions

  • Hemophilia A
  • Hemophilia A, Severe
  • Factor VIII (FVIII)
  • FVIII Deficiency
  • Carrier of Hemophilia A
  • Inhibitors
  • Pregnancy
  • Maternal Blood Loss
  • Pregnancy Complications
  • Bleeding Disorder
  • Hemorrhage, Postpartum
  • Alloimmunization
  • X-Linked

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • RTI International

    collaborator OTHER

  • Emory University

    collaborator OTHER

  • University of Washington

    lead OTHER

Principal Investigators

  • Jill M Johnsen, MD · University of Washington

  • Grier Page, PhD · RTI International

  • Shannon Meeks, MD · Emory University

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-31
Primary Completion
2029-08-31
Completion
2029-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07414511 on ClinicalTrials.gov